October 27, 2017 / 8:25 AM / 2 months ago

BRIEF-ViiV Healthcare announces positive phase 3 results from BRIGHTE study of fostemsavir

Oct 27 (Reuters) - Glaxosmithkline Plc

* ‍GSK - VIIV HEALTHCARE ANNOUNCES POSITIVE PHASE 3 RESULTS FROM BRIGHTE STUDY OF FOSTEMSAVIR IN HEAVILY TREATMENT-EXPERIENCED PATIENTS WITH HIV​

* REGULATORY SUBMISSIONS ARE CURRENTLY ANTICIPATED TO TAKE PLACE IN 2019/2020 TIMEFRAME.​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below